5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Alkem Laboratories Ltd.

•
alkemlabs.comBSE: 539523NSE: ALKEM
Market Cap₹ 61,456 Cr.
Current Price
High / Low₹ 5,934 / 5,075
Stock P/E28.8
Book Value₹ 1,218
Price to Book4.53
Dividend Yield1.03 %
ROCE18.9 %
ROE16.6 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Operating margins have improved to 24.4% from 17.3%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.00x)
  • Company comfortably covers its interest (45.0x coverage)
  • Company has a consistent dividend-paying track record
  • Company generates healthy free cash flow

CONS

  • Promoter holding has decreased over last 2 years: -6.7pp
  • Total debt has risen sharply - up 45.3% year on year
  • Company has delivered a poor profit growth of 5.3% over past five years
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 6.0% over past five years
  • Effective tax rate is unusually low at 13.4% - earnings may be flattered

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MIDCAP 150NIFTY PHARMANIFTY MIDCAP 100NIFTY 500NIFTY HEALTHCARE
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.ALKEM5140.0028.4861456.411.03520.98-22.003740.1510.9521.2820.47
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,2532,6352,0091,8682,1272,3552,2872,0452,3722,5422,4912,2582,668
1,9191,9801,5171,5601,5661,7141,6291,7481,7521,7711,8021,9142,006
Operating Profit334655492309561640658297620771689344662
OPM %14.81%24.85%24.51%16.52%26.39%27.19%28.77%14.51%26.16%30.32%27.67%15.23%24.81%
656244711061201691121311019386137
Interest21192120211721171313161618
Depreciation58595768636168925959617857
Profit before Tax319639459292583682738300680801706336798
Tax %14.89%-1.22%0.84%10.31%6.44%5.89%8.42%24.66%8.45%9.62%11.90%35.42%28.61%
Net Profit271647455262546642676226622724622217570
22.7054.0738.0821.8945.6453.6856.5618.8952.0460.5352.0318.1647.67

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
4,5485,2815,7146,6777,2208,8309,0557,9648,8139,6649,959
3,6704,3084,6685,2095,2717,0197,6786,2936,6577,2507,494
Operating Profit8789731,0461,4681,9491,8101,3771,6712,1562,4142,466
OPM %19.30%18.43%18.30%21.98%26.99%20.50%15.21%20.98%24.46%24.98%24.76%
1171016896177200266242507422418
Interest2432283943388680765762
Depreciation76108141187199219230239284257255
Profit before Tax8949349441,3381,8841,7531,3271,5942,3042,5232,641
Tax %1.26%23.38%15.27%5.50%10.57%12.10%14.51%2.11%9.28%13.38%19.25%
Net Profit8837168001,2641,6851,5411,1341,5612,0902,1852,133
EPS73.8659.8766.90105.75140.93128.9094.88130.53174.80182.78—
Dividend Payout %20.30%21.71%23.91%23.64%21.28%26.37%52.69%30.64%25.74%29.00%—

COMPOUNDED SALES GROWTH

10 Years:
10%
5 Years:
6%
3 Years:
2%

COMPOUNDED PROFIT GROWTH

10 Years:
13%
5 Years:
6%
3 Years:
26%

STOCK PRICE CAGR

10 Years:
12%
5 Years:
6%
3 Years:
12%
1 Year:
-3%

RETURN ON EQUITY

10 Years:
18%
5 Years:
16%
3 Years:
17%
Last Year:
17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 7

₹ 5

Rs.10.0000 per share(500%)Final Dividend

2026

Feb 20

₹ 21.50

Rs.43.0000 per share(2150%)Interim Dividend

2025

Aug 8

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2025

Feb 14

₹ 18.50

Interim Dividend

2024

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2024

Feb 16

₹ 17.50

Interim Dividend

2023

Aug 10

₹ 5

Rs.10.0000 per share(500%)Final Dividend

2023

Feb 17

₹ 12.50

Interim Dividend

2023

Feb 17

₹ 7.50

2022

Aug 8

₹ 2

Rs.4.0000 per share(200%)Final Dividend

2022

Feb 10

₹ 15

Interim Dividend

2021

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2021

Feb 11

₹ 12.50

Interim Dividend

2020

Feb 13

₹ 11

Interim Dividend

2018

Aug 23

₹ 3.50

Rs.7.0000 per share(350%)Final Dividend

2018

Feb 16

₹ 3

Interim Dividend

2017

Aug 31

₹ 4.50

Rs.9.0000 per share(450%)Final Dividend

2016

Nov 23

₹ 3

Rs.6.0000 per share(300%)Interim Dividend

2016

Mar 18

₹ 4.85

Rs.9.7000 per share (485%) Second Interim Dividend

2026

Aug 5

₹ 5

Rs.10.0000 per share(500%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital24242424242424242424
4,3694,8615,4416,2577,6028,7209,32610,53112,29813,975
3805575121,2661,3792,2901,1781,088521717
Trade Payables6858197548129531,1111,0761,5711,4641,476
-150-25-76-72-140-2442-463-140-453
Total Liabilities5,3076,2366,6568,2879,81812,12011,64612,75114,16615,739
1,1261,4711,6061,8371,7581,8821,8251,7821,5911,550
Capital Work in Progress218299382314323232185504686
1,5181,5441,6961,9562,1522,5293,0062,8294,4075,552
8591,0249911,0931,5131,9761,7251,8501,5231,632
1079111212121,7541,5601,567
Cash & Bank1992783987661,6732,2972,1641,0661,0561,289
1,3781,6121,5732,3112,3863,1922,7303,4213,9844,063
Total Assets5,3076,2366,6568,2879,81812,12011,64612,75114,16615,739

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7045009509161,6461,6341,6621,6872,1891,969
Cash from Investing-362-273-313-995-1,121-1,669197-866-1,007-1,461
Cash from Financing-125-60-276173-209437-1,711-959-1,037-673
13-15156-141-567-77-138145-165

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
56.3855.6655.6655.1353.0451.2051.2051.2049.70
8.699.0210.159.409.119.479.9710.1510.41
18.5619.2118.0119.4221.8021.9321.5421.3922.64
Government0.000.000.000.000.000.000.000.000.00
16.3616.1016.1816.0516.0517.4017.3017.2517.25

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Press Release

2026-09-08 - Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum".

2026-08-27
Shareholders meeting

2026-08-27 - Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Outcome of the 52nd Annual General Meeting of the Company and Disclosure of voting results thereat.

2026-08-20
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Alkem Laboratories Limited has informed the Exchange about Q1 FY2027 - Earnings Conference Call Transcript

2026-08-17
Shareholders meeting

2026-08-17 - Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting)

2026-08-15
Copy of Newspaper Publication

2026-08-15 - Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-14
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Link of Recording

2026-08-14
Trading Window

2026-08-14 - Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

2026-08-14
General Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations ).

2026-08-14
Investor Presentation

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Investor Presentation

News

Recent coverage and analyst commentary for ALKEM

Loading news…

🤖

AI Stock Analyst

Alkem Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login